Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05725057
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-15
First Post:
2023-01-26
Brief Title:
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Sponsor:
Artax Biopharma Inc
Organization:
Artax Biopharma Inc
Study Overview
Official Title:
A Phase 2a Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety
Detailed Description:
This is a Phase 2a Proof of Concept randomized double-blind placebo-controlled study to investigate the safety and tolerability of AX-158 in patients with mild to moderate Psoriasis Participants will be randomized 21 to receive AX-158 or Placebo A total of 30 participants will be treated for 28 days and followed for an additional 30 days for safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None